Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 13/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223869 | 1.00 | CFD (0.42) | CFDCTSSCTSKSCN9ATDP1 | |
| SCHEMBL4888653 | 0.88 | TDP1 (0.52) | CTSSCTSKSCN9ATDP1 | |
| SCHEMBL4888640 | 0.88 | TDP1 (0.52) | CTSSCTSKSCN9ATDP1 | |
| SCHEMBL5223701 | 0.83 | DPP4 (0.50) | CFD | |
| SCHEMBL5223707 | 0.83 | DPP4 (0.50) | CFD | |
| SCHEMBL6298469 | 0.82 | TDP1 (0.56) | CTSSCTSKSCN9ATDP1ATM | |
| SCHEMBL8294401 | 0.82 | TDP1 (0.56) | CTSSCTSKSCN9ATDP1ATM | |
| SCHEMBL14102471 | 0.82 | KLK5 (0.54) | TDP1 | |
| SCHEMBL8505388 | 0.80 | CTSK (0.47) | CTSSCTSKSCN9AATMPTPN1 | |
| SCHEMBL4921729 | 0.80 | CTSK (0.47) | CTSSCTSKSCN9AATMPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406872-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK & CO INC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7098239-B2 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK & CO., INC (US) | 2006-08-29 | — | — | US | disclosed |
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176428-A1 | Dipeptidyl peptidase inhibitors for the treatment of diabetes | DPP4, DPP3, DPP9 | CFD 1454/4885CTSS 1619/4885CTSK 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.